Novavax, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NVAX research report →
Companywww.novavax.com
Novavax, Inc. , a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.
- CEO
- John Charles Jacobs
- IPO
- 1995
- Employees
- 952
- HQ
- Gaithersburg, MD, US
Price Chart
Valuation
- Market Cap
- $1.52B
- P/E
- -17.23
- P/S
- 2.56
- P/B
- -10.46
- EV/EBITDA
- -27.91
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 84.64%
- Op Margin
- -11.19%
- Net Margin
- -14.73%
- ROE
- 89.73%
- ROIC
- -9.50%
Growth & Income
- Revenue
- $1.12B · 64.69%
- Net Income
- $440.30M · 334.83%
- EPS
- $2.72 · 321.14%
- Op Income
- $563.27M
- FCF YoY
- -149.40%
Performance & Tape
- 52W High
- $11.97
- 52W Low
- $6.13
- 50D MA
- $8.90
- 200D MA
- $8.31
- Beta
- 2.37
- Avg Volume
- 4.74M
Get TickerSpark's AI analysis on NVAX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 25, 26 | Newton Charles W. | other | 9,520 |
| Apr 25, 26 | Newton Charles W. | other | 9,520 |
| Apr 14, 26 | Walker Robert Edward | other | 99,500 |
| Apr 14, 26 | Walker Robert Edward | other | 66,000 |
| Apr 14, 26 | Walker Robert Edward | other | 0 |
| Apr 14, 26 | Walker Robert Edward | other | 11,500 |
| Apr 14, 26 | Walker Robert Edward | other | 26,300 |
| Apr 14, 26 | Walker Robert Edward | other | 22,510 |
| Apr 14, 26 | Walker Robert Edward | other | 18,826 |
| Mar 10, 26 | Shiver John W. | other | 7,947 |
Our NVAX Coverage
We haven't published any research on NVAX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NVAX Report →